{
  "docId": "019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "docSlug": "0c35b41cdbb80526e1ab822bf08f9a7e",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 49 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 23,
  "pageCount": 49,
  "prevPage": 22,
  "nextPage": 24,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Includes a biological pathway diagram and a comparison of circulating concentrations.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7c08-73a8-a4fa-ba974b61b2ac/23",
  "deckHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac",
  "deckJsonHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac.json",
  "deckAnchorHref": "/decks/019de073-7c08-73a8-a4fa-ba974b61b2ac#slide-23",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.18,
        "x": 0.44,
        "y": 0.35
      },
      "kind": "callout",
      "text": "Factor D inhibition blocks AP, leaving classical and lectin intact",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9cb1447-570a-415b-bd42-43001bb561c2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.25,
        "x": 0.21,
        "y": 0.25
      },
      "kind": "image",
      "text": "Pathway diagram showing Lectin, Classical, and Alternative pathways with Factor D inhibition point",
      "attrs": null,
      "subkind": "infographic",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c233d84e-9023-428a-b013-112af0839970",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.28,
        "x": 0.68,
        "y": 0.67
      },
      "kind": "list",
      "text": "Factor D more tractable target given lower circulating concentration in plasma; Factor B is an acute phase reactant, circulating levels increase during inflammation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1948f595-b783-480c-9702-fa5c95404e3f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.05,
        "x": 0.87,
        "y": 0.45
      },
      "kind": "metric",
      "text": "0.08 µM Factor D",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "20de05fd-af26-4551-a9c3-70d8f6edd57c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.05,
        "x": 0.74,
        "y": 0.45
      },
      "kind": "metric",
      "text": "2.15 µM Factor B",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8fd6bb97-c267-4e08-8654-cf46ec339330",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.17,
        "x": 0.03,
        "y": 0.44
      },
      "kind": "paragraph",
      "text": "Alternative Pathway (AP) dysregulation triggers uncontrolled cascade of reactions, which may lead to cell destruction and harmful inflammation",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0cefaa8f-c521-45d6-8e02-55c654541d7f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.18,
        "x": 0.44,
        "y": 0.51
      },
      "kind": "paragraph",
      "text": "In vitro analysis of small molecules, ALXN2040 and ALXN2050, demonstrate high affinity for Factor D and significantly reduced complement-mediated haemolysis at low concentrations",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b77e06e-a1a2-423c-99ea-c2b2e66ffbc6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Expanding into proximal complement (AP) inhibition",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cd9fbcba-00d7-492b-9d96-3cac5ee43eba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.7,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Novel small molecule, oral Factor D portfolio with ALXN2040, ALXN2050, ALXN2080",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa01e2f7-5ff2-474c-a443-c89148dd7f66",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 29,
      "from": 20,
      "beatId": "c770ee9a-756c-43b6-a68c-b1bacde19cb7",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document provides data and evidence to support the effectiveness of AstraZeneca's medicines",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 29,
      "from": 20,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "4a5c4464-72f0-460e-8bff-ebe93fab6142",
      "evidence": "The document highlights the potential for quick wins and big bets in the rare disease space",
      "position": 2,
      "objective": "What are the key opportunities for AstraZeneca's Rare Disease division",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}